Benucci Maurizio, Damiani Arianna, Manfredi Mariangela, Infantino Maria, Grossi Valentina, Li Gobbi Francesca
Rheumatology Unit, S.Giovanni di Dio Hospital, Florence, Italy.
Immunology and Allergology Laboratory Unit, S.Giovanni di Dio Hospital, Azienda USL-Toscana Centro, Florence, Italy.
Clinicoecon Outcomes Res. 2019 Jun 7;11:405-409. doi: 10.2147/CEOR.S192910. eCollection 2019.
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that affects joints with swelling and progressive joint destruction. The pathology leads to a progressive disability with an impact on the quality of life of the patients. Strategies to reduce in-patient care costs could have a considerable impact on lowering the direct medical costs of RA in Italy. Abatacept, a selective T-cell costimulation modulator, is a valuable treatment option for patients with moderate-to-severe RA. A search using the keywords "cost-effectiveness analysis", "budget impact model", "abatacept", and "rheumatoid arthritis" was carried out on PubMed. Abatacept in the first- and second-treatment lines has been evaluated in our research. We evaluated patients with inadequate MTX response, inadequate anti-TNF agents response, switch studies and real-world data. Furthermore, in our research, we evaluated the main head-to-head studies published.
类风湿关节炎（RA）是一种慢性炎症性疾病，会导致关节肿胀并进行性破坏。这种病理状况会导致患者逐渐残疾，影响其生活质量。降低住院护理成本的策略可能会对降低意大利RA的直接医疗成本产生重大影响。阿巴西普是一种选择性T细胞共刺激调节剂，对于中重度RA患者是一种有价值的治疗选择。我们在PubMed上使用关键词“成本效益分析”“预算影响模型”“阿巴西普”和“类风湿关节炎”进行了检索。我们的研究评估了阿巴西普在一线和二线治疗中的情况。我们评估了甲氨蝶呤（MTX）反应不足、抗TNF药物反应不足的患者、换药研究及真实世界数据。此外，在我们的研究中，我们评估了已发表的主要头对头研究。
